As per the Chinese guideline of prevention and treatment for chronic hepatitis B (2015 update), antiviral drugs approved for pediatric patients include nucleos(t)ide analogues and IFNα; however, IFNα is not recommended for children under 1 year of age.[6] Given the patient’s age of 8 months, an initial oral dose of LAM at 0.05 g/day was administered. This evidence concerns the gene IFNA2 and chronic hepatitis B virus infection.